Co-amoxiclav is the British Approved Name, in the British Pharmacopoeia, for the combination antibiotic containing amoxicillin and clavulanic acid. This name, unlike co_trimoxazole, has not been widely adopted internationally and the combination product is usually referred to by various names such as amoxicillin with clavulanic acid or amoxicillin+clavulanate or simply by the trade name. Co_amoxiclav is currently marketed by GlaxoSmithKline under the trade name Augmentin®.

The combination of amoxicillin, a β-lactam antibiotic; with clavulanic acid, a β-lactamase inhibitor; results in an antibiotic with an increased spectrum of action and restored efficacy against β-lactamase producing amoxicillin-resistant bacteria.